Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Jan;44(1):226-9.
doi: 10.1128/AAC.44.1.226-229.2000.

In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens

F Barchiesi  1 , D Arzeni, A W Fothergill, L F Di Francesco, F Caselli, M G Rinaldi, G Scalise
Affiliations

In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens

F Barchiesi et al. Antimicrob Agents Chemother. 2000 Jan.

Abstract

A broth microdilution method performed in accordance with the National Committee for Clinical Laboratory Standards guidelines was used to compare the in vitro activity of the new antifungal triazole SCH 56592 (SCH) to that of fluconazole (FLC), itraconazole (ITC), and ketoconazole (KETO) against 257 clinical yeast isolates. They included 220 isolates belonging to 12 different species of Candida, 15 isolates each of Cryptococcus neoformans and Saccharomyces cerevisiae, and seven isolates of Rhodotorula rubra. The MICs of SCH at which 50% (MIC(50)) and 90% (MIC(90)) of the isolates were inhibited were 0.06 and 2.0 microg/ml, respectively. In general, SCH was considerably more active than FLC (MIC(50) and MIC(90) of 1.0 and 64 microg/ml, respectively) and slightly more active than either ITC (MIC(50) and MIC(90) of 0.25 and 2.0 microg/ml, respectively) and KETO (MIC(50) and MIC(90) of 0.125 and 4.0 microg/ml, respectively). Our in vitro data suggest that SCH has significant potential for clinical development.

PubMed Disclaimer

References

    1. Barchiesi F, Tortorano A M, Falconi Di Francesco L, Cogliati M, Scalise G, Viviani M A. In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J Antimicrob Chemother. 1999;43:295–299. - PubMed
    1. Como J A, Dismukes W E. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994;330:263–272. - PubMed
    1. Galgiani J N, Lewis M L. In vitro studies of activities of the antifungal triazole SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1997;41:180–183. - PMC - PubMed
    1. Graybill J R, Bocanegra R, Najvar L K, Loebenberg D, Luther M F. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother. 1998;42:2467–2473. - PMC - PubMed
    1. Law D, Moore C B, Denning D W. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother. 1997;41:2310–2311. - PMC - PubMed

Publication types

LinkOut - more resources